NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
Inovio Pharmaceuticals
Jonsson Comprehensive Cancer Center
Sapience Therapeutics
Centre Francois Baclesse
Washington University School of Medicine
Nerviano Medical Sciences
TME Pharma AG
Centre Jean Perrin
University of Louisville